Certain melanoma patients (those with locoregionally advanced, resectable melanoma) have a high risk of relapse and death from the cancer. Some, those with clinically detected nodal disease, have a mortality risk as high as 75%.
Previous work—through the Checkmate-915 trial—investigated if the addition of ipilimumab to nivolumab in the adjuvant setting improved recurrence-free survival (RFS) compared to nivolumab alone. Not only did it not work, it increased toxicity.
